RxDoctor Payments Data

Miguel Antelo, MD

Urology · Nashua, NHNPI 1720069545

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,650 of the $4,286 with a category attached, or 61.8%. Gyrus ACMI, Inc. accounts for 61.8% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $2,710, more than ten times the $39 reported in 2019.

$4,286in general payments, 2019–2025

Across 26 payments — averaging $164.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gyrus ACMI, Inc.$3K
  • Boston Scientific$1K
  • Dentsply IH AB$200
  • AbbVie$55
  • Laborie Medical Technologies Corp.$30
  • Teleflex LLC$29
  • plus $95 from 4 others

What the payments were for

  • Consulting fees$2,65062%
  • Travel & lodging$1,05925%
  • Food & beverage$57713%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gyrus ACMI, Inc.2$2,650
Boston Scientific8$1,227
Dentsply IH AB8$200
AbbVie2$55
Laborie Medical Technologies Corp.1$30
Teleflex LLC1$29
Tempus AI, Inc1$25
Rochester Medical Corporation1$24
Medtronic1$24
Astellas Pharma US Inc1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,286 in reported general payments places this provider in the 80th percentile of 61 urology providers in New Hampshire.

See all urology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$125,933
Medicare patients
544
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron116$78,063
GemtesaVibegron31$26,169
Mirabegron ErMirabegron28$15,264
Tamsulosin Hcl479$9,111
Alfuzosin Hcl ErAlfuzosin Hcl164$3,789
Finasteride193$3,520
Oxybutynin Chloride ErOxybutynin Chloride146$3,245
Solifenacin Succinate43$2,653
Trospium Chloride38$2,383
Silodosin27$1,503
Estradiol18$1,143
Potassium Citrate ErPotassium Citrate13$1,136
Bethanechol Chloride11$859
Cefpodoxime Proxetil15$633
Fesoterodine Fumarate ErFesoterodine Fumarate11$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$23$78,063116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 61 urology providers in New Hampshire.

Other urology in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →